Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02516605 · ClinicalTrials.gov registry record · Phase 2
A Multi-part, Double Blind Study to Assess Safety, Tolerability and Efficacy of Tropifexor (LJN452) in PBC Patients
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
NCT02516605 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 61 participants.
The verdict
NCT02516605, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
Study Summary
A multi-part study to assess safety, tolerability and efficacy of tropifexor (LJN452) in patients with primary biliary cholangitis
Interventions
- DRUG Part 1: LJN452
- DRUG Part 1: Placebo
- DRUG Part 2: LJN452 Dose level 1
- DRUG Part 2: Placebo
- DRUG Part 2: LJN452 Dose level 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2015-09-09 |
| Est. Completion | 2018-08-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02516605
The ClinicalTrials.gov registry entry for NCT02516605 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Part 1: LJN452 is the first listed.
NCT02516605 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02516605 about?
NCT02516605 is a clinical study titled "A Multi-part, Double Blind Study to Assess Safety, Tolerability and Efficacy of Tropifexor (LJN452) in PBC Patients". A multi-part study to assess safety, tolerability and efficacy of tropifexor (LJN452) in patients with primary biliary cholangitis
What is the current status of trial NCT02516605?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2015-09-09. Estimated completion is 2018-08-02.
What interventions are being tested in trial NCT02516605?
The interventions under investigation include: Part 1: LJN452 (DRUG), Part 1: Placebo (DRUG), Part 2: LJN452 Dose level 1 (DRUG), Part 2: Placebo (DRUG), Part 2: LJN452 Dose level 2 (DRUG).
Who is sponsoring clinical trial NCT02516605?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.